Use of a Topical XXXX -Based Hemostatic Agent in Shoulder Arthroplasty.

@entity1 @entity556 @entity174 @entity190 @entity1503
Shoulder arthroplasty is associated with significant @entity190 , often requiring blood transfusion. Hemostatic agents are used in various surgical specialties to minimize @entity190 , but to date few studies have examined their efficacy in shoulder arthroplasty. We retrospectively reviewed 211 consecutive shoulder arthroplasty cases performed by a single surgeon. Our hypothesis was that @entity1 treated with a topical @entity556 prepared with a hemostatic matrix (Surgiflo) would have decreased perioperative @entity190 . @entity1 with @entity174 or preexisting @entity1503 were excluded. Control @entity1 were managed December 2012 through April 2013. Study @entity1 were managed May 2013 through August 2013 using the same surgical technique with the additional application of the hemostatic agent before closure. Charts were reviewed for demographics, estimated @entity190 , drain output, transfusion rates, and complications. @entity190 was calculated using a validated method. There were no differences in estimated @entity190 (P = .301), drain output (P = .906), or hidden @entity190 (P = .601) between groups. There was no increased incidence of transfusion between study (25%) and control (20%) groups (P = .407). No increased complications resulted from use of the hemostatic agent (P = .764). On the basis of these results, we cannot conclude that this topical hemostatic agent is effective as a @entity190 management tool in shoulder arthroplasty.
